Reaction

Hypothalamo-Pituitary Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,425 reports · 42 co-occurring drugs

As of the last recalculation, Hypothalamo-Pituitary Disorder appears in 1,425 FAERS reports alongside 42 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 62.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ipilimumab	164	62.6	62.8
Fluticasone Furoate	46	57.3	57.5
Fesoterodine Fumarate	34	46.9	47.1
Nivolumab	206	36.2	36.3
Pembrolizumab	178	28.1	28.1
Busulfan	25	23.6	23.6
Ado-Trastuzumab Emtansine	13	22.7	22.8
Octreotide Acetate	46	22.6	22.7
Dalteparin Sodium	14	19.5	19.5
Somatropin	89	18.8	18.8
Durvalumab	25	18.3	18.3
Mesna Injection	10	17.8	17.8
Mesna	10	17.5	17.5
Docusate Sodium - Sennosides	37	17.2	17.2
Raloxifene Hydrochloride	16	16.2	16.2
Zinc	25	15.1	15.1
Zinc Chloride	25	15.0	15.0
Zinc Gluconate	26	14.8	14.8
Calcium Gluconate	12	14.7	14.7
Sodium Bicarbonate	22	14.0	14.0
Sodium Bicarbonate Injection,	22	14.0	14.0
Temazepam	35	13.9	13.9
Acetaminophen And Codeine	10	12.1	12.1
Candesartan Cilexetil	21	11.8	11.8
Testosterone Cypionate	7	11.5	11.5
Gentamicin	10	11.2	11.2
Loratadine Oral	36	11.0	11.0
Atezolizumab	23	8.8	8.8
Atazanavir	8	8.2	8.2
Pertuzumab	14	7.6	7.6
Axitinib	10	7.5	7.5
Axicabtagene Ciloleucel	5	7.4	7.4
Paclitaxel (Aibumin-Bound)	37	6.7	6.7
Deferasirox	12	6.7	6.7
Pemetrexed Disodium	17	6.6	6.6
Paclitaxel	43	6.5	6.5
Carboplatin	53	6.3	6.3
Ranitidine Hydrochloride	22	6.0	6.0
Rimegepant Sulfate	5	5.8	5.8
Paliperidone	8	5.0	5.0
Vigabatrin	3	3.0	3.0
Lifitegrast	3	2.7	2.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.